肿瘤细胞治疗研究
英文原题：Nanomaterials Mediated Enhancement of CAR-T for HCC: Revolutionizing Immunotherapy Strategies.
肝细胞癌（HCC）因其侵袭性和对常规治疗的耐药性而带来重大挑战。
肝细胞癌（HCC）因其侵袭性强和对常规治疗耐药而带来重大挑战。虽然 CAR-T 疗法在血液系统肿瘤中显示出前景，但其在 HCC 中的应用受到肿瘤微环境（TME）、T 细胞浸润不足和抗原异质性的限制。纳米材料通过增强 CAR-T 细胞的递送、激活、持久性以及克服免疫抑制性 TME，提供了一种有前景的解决方案。本综述聚焦于纳米颗粒在 CAR-T 疗法中的应用，重点介绍基于纳米材料的 mRNA 递送、光热重塑和水凝胶平台方面的最新进展。此外，纳米材料增强的成像工具能够实时监测 CAR-T 细胞活性，提高治疗精准度和安全性。通过解决当前局限性，纳米材料介导的 CAR-T 疗法有潜力改变 HCC 治疗，为更有效和个性化的癌症免疫治疗铺平道路。
Hepatocellular carcinoma (HCC) presents significant challenges due to its aggressive nature and resistance to conventional treatments. While CAR-T therapy has shown promise in hematologic cancers, its application in HCC is limited by the tumor microenvironment (TME), insufficient T-cell infiltration, and antigenic heterogeneity. Nanomaterials offer a promising solution by enhancing CAR-T cell delivery, activation, persistence, and overcoming the immunosuppressive TME. This review focuses on the application of nanoparticles in CAR-T therapy, highlighting recent advancements in nanomaterials-based mRNA delivery, photothermal remodeling, and hydrogel platforms. Furthermore, nanomaterials-enhanced imaging tools enable real-time monitoring of CAR-T cell activity, improving therapeutic precision and safety. By addressing current limitations, nanomaterial-mediated CAR-T therapy holds the potential to transform HCC treatment, paving the way for more effective and personalized cancer immunotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
